Revenue of AbbVie's Humira 2011-2023
This statistic illustrates the revenue of pharmaceutical product Humira from 2011 to 2023. In 2023, AbbVie's top product generated 14.4 billion U.S. dollars of revenue. Abbot Laboratories was a U.S.-based global pharmaceutical and healthcare products company, headquartered in Chicago, Illinois. In January 2013, Abbott was separated into two companies: Abbott and AbbVie. Abbott is now specialized on medical products, while AbbVie is responsible for research-based pharmaceuticals. On May 8, 2020, AbbVie completed the acquisition of Allergan plc.
Abbvie's top product Humira
AbbVie’s Humira has increased its revenue from 2011 to 2022, generating 7.9 billion U.S. dollars in 2011 and a record high of 21.2 billion U.S. dollars in 2022. However, with generic versions of Humira entering the U.S. market in 2023, the revenue dropped dramatically by over seven billion dollars. In the United States, AbbVie expended 236 million U.S. dollars on advertising for Humira in 2021.
Adalimumab is marketed as Humira, a biotech pharmaceutical product. The name “Humira” is derived from “human monoclonal antibody in rheumatoid arthritis”. The inhibiting anti-inflammatory drug acts by inhibiting the activation of tumor necrosis factor-alpha (TNF) which can downregulate inflammation caused by autoimmune diseases. For example, it can be used for rheumatoid arthiritis which attacks the joints and can also impact tissues and organs. Humira can be also be used for diseases such as Plaque psoriasis and Crohn’s disease. Humira's price was an hot debated topic. The drug's price has effectively increased 60 percent within the period of 2016-2021, the largest price increase among blockbuster drugs.
Abbvie's top product Humira
AbbVie’s Humira has increased its revenue from 2011 to 2022, generating 7.9 billion U.S. dollars in 2011 and a record high of 21.2 billion U.S. dollars in 2022. However, with generic versions of Humira entering the U.S. market in 2023, the revenue dropped dramatically by over seven billion dollars. In the United States, AbbVie expended 236 million U.S. dollars on advertising for Humira in 2021.
Adalimumab is marketed as Humira, a biotech pharmaceutical product. The name “Humira” is derived from “human monoclonal antibody in rheumatoid arthritis”. The inhibiting anti-inflammatory drug acts by inhibiting the activation of tumor necrosis factor-alpha (TNF) which can downregulate inflammation caused by autoimmune diseases. For example, it can be used for rheumatoid arthiritis which attacks the joints and can also impact tissues and organs. Humira can be also be used for diseases such as Plaque psoriasis and Crohn’s disease. Humira's price was an hot debated topic. The drug's price has effectively increased 60 percent within the period of 2016-2021, the largest price increase among blockbuster drugs.
